Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 6/20 | 0.65 |
| ▸ | AKR1B1 | P15121 | 4/20 | 0.47 |
| ▸ | IDO1 | P14902 | 2/20 | 0.46 |
| ▸ | AKR1B10 | O60218 | 3/20 | 0.45 |
| ▸ | CA4 | P22748 | 2/20 | 0.45 |
| ▸ | CA12 | O43570 | 1/20 | 0.45 |
| ▸ | CA6 | P23280 | 1/20 | 0.45 |
| ▸ | CA5A | P35218 | 1/20 | 0.45 |
| ▸ | CA7 | P43166 | 1/20 | 0.45 |
| ▸ | CA9 | Q16790 | 1/20 | 0.45 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.45 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | TTR | P02766 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21678780 | 1.00 | HCAR2 (0.65) | HCAR2AKR1B1IDO1AKR1B10CA4 | |
| SCHEMBL2340792 | 0.93 | HCAR2 (0.53) | HCAR2AKR1B1IDO1AKR1B10CA4 | |
| SCHEMBL78103 | 0.93 | HCAR2 (0.53) | HCAR2AKR1B1IDO1AKR1B10CA4 | |
| SCHEMBL21678700 | 0.85 | MAPT (0.52) | HCAR2AKR1B1IDO1AKR1B10CA12 | |
| SCHEMBL21678773 | 0.85 | AKR1B1 (0.47) | HCAR2AKR1B1IDO1AKR1B10CA4 | |
| SCHEMBL5312885 | 0.84 | LMNA (0.67) | AKR1B1AKR1B10CA4CA12CA6 | |
| SCHEMBL5312883 | 0.84 | LMNA (0.67) | AKR1B1AKR1B10CA4CA12CA6 | |
| SCHEMBL5176891 | 0.83 | IDO1 (0.46) | HCAR2AKR1B1IDO1AKR1B10CA4 | |
| SCHEMBL21678750 | 0.83 | APP (0.50) | HCAR2AKR1B1IDO1AKR1B10LMNA | |
| SCHEMBL10339805 | 0.82 | HCAR2 (0.63) | HCAR2KDM4ESMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11866401-B2 | Salicyl fumarate derivative and its application in the treatment of Parkinson's disease and other neurodegenerative diseases | CHONGQING NEUROPARK BIOSCIENCE CO., LTD. (CN) | 2024-01-09 | — | — | US | claimed |
| US-20210179533-A1 | SALICYL FUMARATE DERIVATIVE AND ITS APPLICATION IN THE TREATMENT OF PARKINSON'S DISEASE AND OTHER NEURODEGENERATIVE DISEASES | CHONGQING NEUROPARK BIOSCIENCE CO., LTD. (CN) | 2021-06-17 | — | — | US | claimed |
| EP-3611157-A1 | SALICYLIC ACID-BASED FUMARATE DERIVATIVE AND USE IN TREATMENT OF PARKINSON'S DISEASE AND OTHER NEURODEGENERATIVE DISEASES | Chongqing Neuropark Bioscience Co., Ltd. (CN) | 2020-02-19 | — | — | EP | claimed |
| US-20200048182-A1 | A SALICYL FUMARATE DERIVATIVE AND ITS APPLICATION IN THE TREATMENT OF PARKINSON'S DISEASE AND OTHER NEURODEGENERATIVE DISEASES | CHONGQING NEUROPARK BIOSCIENCE CO., LTD. (CN) | 2020-02-13 | — | — | US | claimed |
| CN-106946701-A | Salicylic acid-based fumarate derivative and application thereof in treating Parkinson's disease and other neurodegenerative diseases | 杨立川 | 2017-07-14 | — | — | CN | claimed |
| EP-2094292-B1 | NITRIC OXIDE-BLOCKED CROSS-LINKED TETRAMERIC HEMOGLOBIN | IKOR INC (US) | 2014-07-09 | — | — | EP | claimed |
| US-20120220529-A1 | NITRIC OXIDE-BLOCKED CROSS-LINKED TETRAMERIC HEMOGLOBIN | IKOR, INC. | 2012-08-30 | — | — | US | claimed |
| EP-2094292-A2 | NITRIC OXIDE-BLOCKED CROSS-LINKED TETRAMERIC HEMOGLOBIN | Ikor, Inc. (US) | 2009-09-02 | — | — | EP | claimed |
| US-7494974-B2 | Carboxymethylated cross-linked tetrameric hemoglobin | IKOR, INC. (US) | 2009-02-24 | — | — | US | claimed |
| WO-2008051689-A2 | NITRIC OXIDE-BLOCKED CROSS-LINKED TETRAMERIC HEMOGLOBIN | IKOR, INC. (US) | 2008-05-02 | — | — | WO | claimed |
| US-20080096805-A1 | deoxygenated, endotoxin-free and stroma-free transport proteins, incapable of binding with nitric oxide, useful as substitutes for erythrocytes in mammals and for treating disorders where oxygen delivery agents are of benefit | IKOR, INC. | 2008-04-24 | — | — | US | claimed |
| US-20080096803-A1 | Carboxymethylated cross-linked tetrameric hemoglobin | IKOR, INC. | 2008-04-24 | — | — | US | claimed |
| EP-4021933-B1 | THIOSUCCINYL-CROSSLINKED HEMOGLOBIN ANALOGS AND METHODS OF USE AND PREPARATION THEREOF | BILLION KING INTERNATIONAL LTD (HK) | 2024-10-09 | — | — | EP | disclosed |
| CN-114341174-B | Succinyl cross-linked hemoglobin analogues and methods of use and preparation thereof | 亿京国际有限公司 | 2024-05-17 | — | — | CN | disclosed |
| US-11866401-B2 | Salicyl fumarate derivative and its application in the treatment of Parkinson's disease and other neurodegenerative diseases | CHONGQING NEUROPARK BIOSCIENCE CO., LTD. (CN) | 2024-01-09 | — | — | US | disclosed |
| US-11866401-B2 | Salicyl fumarate derivative and its application in the treatment of Parkinson's disease and other neurodegenerative diseases | CHONGQING NEUROPARK BIOSCIENCE CO., LTD. (CN) | 2024-01-09 | — | — | US | disclosed |
| US-20040242464-A1 | Non-pyrogenic, endotoxin-frei stroma-free tetrameric hemoglobin | IKOR, INC. | 2004-12-02 | — | — | US | disclosed |
| US-6017943-A | INTRAMOLECULARLY CROSSLINKING HEMOGLOBIN TO FORM A SYNTHETIC BLOOD | ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (US) | 2000-01-25 | — | — | US | disclosed |
| US-5750725-A | USING A SUBSTITUTED POLYETHERS | ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY, A DIVISION OF YESHIVA (US) | 1998-05-12 | — | — | US | disclosed |
| US-5585484-A | USING ETHOXYLATED PHENYLMALEIMIDO COMPOUNDS | ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY, A DIVISION OF YESHIVA UNIVERSITY (US) | 1996-12-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210179533-A1 | SALICYL FUMARATE DERIVATIVE AND ITS APPLICATION IN THE TREATMENT OF PARKINSON'S DISEASE AND OTHER NEURODEGENERATIVE DISEASES | FH, SUCNR1, SDHB | HCAR2 61/4885AKR1B1 450/4885IDO1 3205/4885 |
| US-20200048182-A1 | A SALICYL FUMARATE DERIVATIVE AND ITS APPLICATION IN THE TREATMENT OF PARKINSON'S DISEASE AND OTHER NEURODEGENERATIVE DISEASES | FH, SUCNR1, SDHB | HCAR2 75/4885AKR1B1 361/4885IDO1 3084/4885 |
| US-11866401-B2 | Salicyl fumarate derivative and its application in the treatment of Parkinson's disease and other neurodegenerative diseases | FH, SUCNR1, SDHB | HCAR2 88/4885AKR1B1 483/4885IDO1 3152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.